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Abstract Stroke incidence rates have decreased in
developed countries over the past 40 years, but trends vary
across populations. We investigated whether age-and-sex-
speciﬁc stroke incidence rates and associated risk factors as
well as preventive medication use have changed in Rot-
terdam in the Netherlands during the last two decades. The
study was part of the Rotterdam Study, a large population-
based cohort study among elderly people. Participants were
10,994 men and women aged 55–94 years who were
stroke-free at baseline. Trends were calculated by com-
paring the 1990 subcohort (n = 7516; baseline 1990–1993)
with the 2000 subcohort (n = 2883; baseline 2000–2001).
Poisson regression was used to calculate incidence rates
and incidence rate ratios in age-and-sex-speciﬁc strata. We
further compared the prevalence of stroke risk factors and
preventive medication use in the two subcohorts. In the
1990 subcohort 467 strokes occurred during 45,428 person
years; in the 2000 subcohort 115 strokes occurred in 18,356
person years. Comparing the subcohorts, incidence rates
decreased by 34% in men, but remained unchanged in
women. Blood pressure levels increased between 1990 and
2000, whereas the proportion of current cigarette smokers
decreased in men, but not in women. There was a strong
increase in medication use for treatment of stroke risk
factors across all age categories in both sexes. Our ﬁndings
suggest that in Rotterdam between 1990 and 2008 stroke
incidence rates have decreased in men but not in women.
Keywords Stroke  Epidemiology  Incidence 
Cohort study  Risk factors  Trends
Introduction
The worldwide burden of stroke is predicted to increase
due to increased life expectancy and population aging [1].
On the other hand, in several high-income countries, stroke
mortality trends were predicted to decrease in the decades
ahead [2]. Furthermore, age-speciﬁc stroke incidence rates
have decreased in high-income countries during the past
40 years [3]. However, there are substantial geographic
differences in stroke incidence rates and trends over time
[4]. Currently it is not clear if stroke incidence rates are
changing in the Netherlands.
Stroke is increasingly recognized as a disease that can
be prevented [5]. Knowledge of modiﬁable risk factors and
the availability of primary preventive medication has
resulted in the development of evidence-based guidelines
for the treatment of high-risk individuals [6]. Furthermore,
public health campaigns were initiated to improve aware-
ness of risk factors and to promote lifestyle changes on a
population level. Whether these interventions resulted in a
favorable risk factor proﬁle of the general population and,
in parallel, in a reduction in stroke events is unknown and
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DOI 10.1007/s10654-012-9673-yrequires investigation. Additionally, studies suggest that
women may receive suboptimal treatment of cardiovascu-
lar risk factors because of lower perception of risk by
treating physicians [7]. Therefore sex-speciﬁc changes in
risk factor proﬁles and stroke incidence rates are of par-
ticular interest.
The aim of the present study was to describe temporal
trends in stroke incidence rates in the Netherlands during
the past 20 years, and to investigate changes in preventive
medication use and the prevalence and severity of stroke
risk factors. We particularly aimed to compare patterns
between men and women. All analyses were based on data
from the Rotterdam Study, a large prospective population-
based cohort study among elderly people living in the city
of Rotterdam in the Netherlands.
Methods
Study population
The Rotterdam Study is an ongoing prospective popula-
tion-based cohort study that focuses on causes and conse-
quences of chronic and disabling diseases in the elderly [8].
The cohort started in 1990 and included 7,983 participants
aged C55 years living in Ommoord, a district of the city of
Rotterdam in the Netherlands (participation rate 78%). In
2000, the cohort was expanded with 3,011 people who had
reached the age of 55 or had moved into the district since
the start of the study (response rate 67%). The study was
approved by the Medical Ethics Committee of the Erasmus
MC University Medical Center and all participants gave
written informed consent to participate in the study.
The present study included participants of the 1990
subcohort and the 2000 subcohort who were aged 55–94 at
baseline (n = 10944). Participants who had had a stroke
before baseline (n = 361) and participants who had not
signed consent for the collection of follow-up data from
general practitioners (n = 184) were excluded. This
resulted in 10,399 participants in the population for anal-
ysis (1990 subcohort, n = 7,516; 2000 subcohort,
n = 2,883).
Stroke risk factors and preventive medication use
Trained research physicians visited all participants at home
for ﬁlling in standardized questionnaires about their health
status, medical history and current medication use. Data on
female hormone use, including both oral contraceptive use
and hormone replacement therapy for menopausal com-
plaints, were collected at baseline and classiﬁed as current
use or ever use. Subsequently, participants visited the
research center twice for physical examinations and blood
sampling. Cigarette smoking behavior was classiﬁed as
current, past or never. Blood pressure was measured twice
at the right brachial artery with a random-zero sphygmo-
manometer after 5 min of rest while the subject was in a
sitting position. Hypertension grade I was deﬁned as a
diastolic blood pressure of 90–99 mm Hg or a systolic
blood pressure of 140–159 mm Hg. Hypertension grade II
was deﬁned as a diastolic or systolic blood pressure of
C100/160 mm Hg, and/or use of blood pressure-lowering
medication [9]. Total serum cholesterol, high-density
lipoprotein cholesterol and glucose levels were measured
using an automated enzymatic procedure. Non-fasting
blood samples were obtained from the 1990 subcohort,
fasting blood samples from the 2000 subcohort. Diabetes
mellitus was deﬁned as a fasting glucose level C7.0 mmol/
L, a non-fasting or post-load serum glucose level
C11.1 mmol/L and/or the use of blood glucose-lowering
drugs. Body mass index was calculated as weight (in
kilograms) divided by the square of height (in meters).
Atrial ﬁbrillation was diagnosed when observed on ECG
during the visit to the research center or when reported in
medical records. History of myocardial infarction was
considered positive when self-reported during the inter-
view, observed on ECG during the center visit, and/or
conﬁrmed in medical records.
Assessment of stroke
Stroke was deﬁned according to WHO criteria as a syn-
drome of rapidly developing clinical signs of focal (or
global) disturbance of cerebral function, with symptoms
lasting 24 h or longer or leading to death, with no apparent
cause other than of vascular origin [10]. History of stroke at
baseline was assessed during the baseline interview and
veriﬁed by reviewing medical records. After enrollment,
participants were continuously monitored for incident
stroke through automated linkage of the study database
with ﬁles from general practitioners. Nursing home phy-
sicians’ ﬁles and ﬁles from general practitioners of par-
ticipants who moved out of the district were checked on a
regular basis as well. Additional information was obtained
from hospital records. Potential strokes were reviewed by
research physicians, and veriﬁed by an experienced stroke
neurologist (P.J.K.). Strokes were further classiﬁed as
cerebral infarction or intracerebral hemorrhage based on
neuroimaging reports. If neuroimaging was lacking, a
stroke was classiﬁed as unspeciﬁed. This classiﬁcation
corresponded with ICD-10 codes I61, I63 and I64. Tran-
sient ischemic attacks or subarachnoid hemorrhages were
not included. Participants could contribute person years to
the follow-up for a maximum of 7 years, that is, from
baseline until a ﬁrst-ever stroke occurred, or until death, or
until they reached the age of 95, or, if lost to follow-up,
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to be free of stroke, whichever came ﬁrst, or until they
completed 7 years of follow-up. The follow-up of the 1990
subcohort was complete for 99.8% of potential person
years, the follow-up of the 2000 subcohort for 97.8% of
potential person years.
Statistical analysis
We compared the prevalence of risk factors and preventive
medication use between the 1990 and the 2000 subcohorts,
in strata of men and women, and in 10 year age categories.
ANCOVA was used to calculate age-adjusted P values for
the differences between cohorts. We used Poisson regres-
sion to calculate age-adjusted incidence rates and rate
ratios in 10 year age strata and in the total population aged
55–94. The 1990 subcohort was used as the reference
cohort. During the follow-up period, participants could
move to a higher age category, i.e., we used a dynamic
cohort population. Therefore, participants could contribute
person years to subsequent age categories and could be
included in the ‘‘number at risk’’ in more than one age
category. Stroke events were counted in the age category
the participant belonged to at the moment the stroke
occurred. We further assessed whether overall stroke
incidence rate ratios differed between men and women by
including a multiplicative interaction term (sex * subco-
hort) in the regression model and we calculated incidence
rates and rate ratios in sex-speciﬁc strata.
Results
The prevalence of stroke risk factors and preventive med-
ication use in the 1990 and the 2000 subcohorts are pre-
sented in Table 1 for men and in Table 2 for women. The
prevalence of grade II hypertension increased with age and
was higher in women than in men within both cohorts.
Comparing the 1990 with the 2000 subcohort, we observed
an enormous increase in grade II hypertension over time,
due to an increase of both systolic and diastolic blood
pressure. Blood pressure-lowering medication use had not
increased over time, except for men aged 85–94. The
prevalence of diabetes mellitus and blood glucose-lowering
medication use had increased only in the youngest age
groups (men and women aged 55–64) but remained stable
in the other strata. Serum HDL-cholesterol levels were
higher in women than in men in all age categories. HDL-
cholesterol levels did not vary with age and did not differ
over time. The 2000 subcohort more often used lipid-
lowering medication than the 1990 subcohort. However, in
both subcohorts, lipid-lowering medication use was more
common in the younger than in the older age groups and
more common in men than in women. Body mass index
increased over time and was higher in women than in men.
The proportion of current cigarette smokers decreased in
men, but remained more or less stable in women. In the
1990 subcohort, cigarette smoking was much more fre-
quent in men than in women, but in the 2000 subcohort the
proportion of cigarette smokers among men and women
was almost the same. Men more often had a history of
myocardial infarction than women. From 1990 to 2000, the
prevalence of myocardial infarction had decreased in men
aged 55–64, but was unchanged in other age and sex strata.
The presence of atrial ﬁbrillation increased with age but did
not change over time. Antithrombotic medication use
increased with age and increased enormously over time
both in men and women. We further investigated the use of
sex hormones in women. Though current female hormone
use was uncommon in both subcohorts, the proportion of
women that had ever taken female hormones, either oral
contraceptives or hormone replacement therapy, had
increased enormously over time.
Fig. 1 shows age-and-sex-speciﬁc Kaplan–Meier curves
for the stroke-free survival in the 1990 versus the 2000
subcohort. Age-adjusted stroke incidence rates and inci-
dence rate ratios are shown in Table 3. In the total popu-
lation including both men and women, we observed no
change in age-adjusted stroke incidence rates. However,
after stratiﬁcation for sex, we found that the change in
incidence rate ratios was different in men and women
(Pinteraction = 0.04). In men, stroke incidence rates were
unchanged in the 55–64 year age category, but decreased
in the 65–74, 75–84 and 85–94 year age categories. In all
men (55–94), the overall stroke incidence rate had
decreased with 34%. In women, age-speciﬁc stroke inci-
dence rates showed a variable pattern. Incidence rates
decreased in women aged 55–64, increased in women aged
65–74, and were stable in women aged 75–84 and 85–94.
In all women (55–94), stroke incidence rates had not
changed over time.
Discussion
We investigated trends in stroke incidence in Rotterdam,
the Netherlands from 1990 to 2008 by comparing two
subcohorts of the large population-based Rotterdam Study.
We also investigated changes in stroke risk factors and
preventive medication use. We found that stroke incidence
rates decreased by 34% in men, but remained unchanged
in women. In men, but not in women, the proportion of
current cigarette smokers had decreased. However, both in
men and women, blood pressure levels had increased,
whereas blood pressure lowering medication use was
unchanged. Body mass index also increased in men and
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123women. History of female hormone use, either oral con-
traceptives or hormone replacement therapy, had increased
over time. The use of lipid-lowering medication and anti-
thrombotic medication had increased enormously both in
men and women.
This study has several strengths, including the pro-
spective and population-based design and the large number
of participants. Furthermore, we compared two subcohorts
with the same study design and inclusion criteria at two
different time-periods (1990–1998 versus 2000–2008).
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Fig. 1 Age-and-sex-speciﬁc Kaplan–Meier curves for the stroke-free survival of the 1990 versus the 2000 subcohort
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123Thorough stroke monitoring procedures and the nearly
complete follow-up allowed us to include virtually all
stroke events, even in participants who had not been
referred to a neurologist or admitted to a hospital, for
example people living in nursing homes or participants
who had a fatal stroke. An advantage of this approach was
that the trends we observed have not been inﬂuenced
by changes in referral or admission patterns. However, a
disadvantage was that neuroimaging had not been per-
formed in all stroke patients. Because the 2000 subcohort
had more widely access to brain CT or MRI than the 1990
subcohort, a larger proportion of events in the 2000 sub-
cohort could be subclassiﬁed as ischemic or hemorrhagic
and a smaller proportion remained unspeciﬁed as compared
to the 1990 subcohort. As a consequence, we could not
compare incidence rates of ischemic and hemorrhagic
stroke subtypes.
Another potential limitation of our study is the external
validity of the results obtained. The Rotterdam Study was
performed in the well-deﬁned Ommoord district of Rot-
terdam because the population of this suburb, composed
mainly of white, middle class subjects, was considered to
be representative for the average Dutch population. The
participation rate of eligible persons was high (78% for the
1990 subcohort and 67% for the 2000 subcohort),
minimizing the likelihood of selection bias. Therefore, we
are conﬁdent that the trends we observed over time can be
generalized to the Rotterdam population and even the
Dutch population at large. However, we do not know
whether our results also hold for populations with a
different ethnic or socio-economic composition. We further
should note the fact that our study participants were
informed about their cardiovascular risk factors at baseline.
Because this may have had a positive impact on prevention
and treatment, it is possible that incidence rates obtained
from our study cohort may be somewhat lower than actual
incidence rates in the general population.
Many previous studies have reported stroke incidence
rates and temporal trends. Incidence rates are, however,
often hard to compare across studies, because of differ-
ences in study design and case ascertainment methods.
Trends should be comparable if within-study case ascer-
tainment methods have not changed over time. When we
compare our ﬁndings to results of other studies covering
the same time-period, most studies reported either declin-
ing [11–17] or stable stroke incidence rates [18–20]. None
of the studies, except one, reported divergent trends for
men and women [11]. Associated changes in risk factors
were usually favorable, contradictory to the increase in
blood pressure levels we observed [14, 16]. However, the
Table 3 Stroke incidence rates and rate ratios
1990 Subcohort 2000 Subcohort
At risk
N*
Events
n
Person
years
Incidence rate/1,000
person years
At risk
N*
Events
n
Person
years
Incidence rate/1,000
person years
Incidence rate ratio
(95% CI)
Total population
55–64 2,667 28 11289.9 2.65 1,864 19 8689.9 2.33 0.88 (0.49–1.58)
65–74 4,514 120 18261.6 5.77 1,837 39 6263.1 6.43 1.11 (0.77–1.61)
75–84 3,223 196 11845.6 16.44 676 36 2628.7 13.58 0.83 (0.58–1.18)
85–94 1,325 123 4031.1 27.71 2,39 21 774.8 25.85 0.93 (0.59–1.48)
All ages 7,516 467 45428.2 7.70 2,883 115 18356.5 6.85 0.89 (0.72–1.10)
Men
55–64 1,140 14 4755.1 3.32 815 11 3826.5 3.30 1.00 (0.45–2.20)
65–74 1,931 72 7883.0 8.47 820 18 2824.2 6.46 0.76 (0.45–1.29)
75–84 1,177 79 4133.5 18.90 282 11 1024.6 10.62 0.56 (0.30–1.06)
85–94 316 28 845.0 28.05 73 3 217.0 12.95 0.46 (0.14–1.53)
All ages 2,948 193 17616.6 9.01 1,251 43 7892.2 5.95 0.66 (0.47–0.92)
Women
55–64 1,527 14 6534.8 2.05 1,049 8 4863.4 1.58 0.77 (0.32–1.84)
65–74 2,583 48 10378.6 3.70 1,017 21 3439.0 6.34 1.71 (1.01–2.90)
75–84 2,046 117 7712.1 15.10 394 25 1604.1 15.47 1.02 (0.66–1.58)
85–94 1,009 95 3186.1 27.61 166 18 557.8 30.89 1.12 (0.68–1.85)
All ages 4,568 274 27811.6 6.79 1,632 72 10464.3 7.38 1.09 (0.83–1.41)
Incidence rates and incidence rate ratios are adjusted for age
* Persons could contribute person years to more than one age category
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123ARCOS study from New Zealand also reported a decline in
men but not in women, despite an increase in blood pres-
sure levels, diabetes and body mass index, but a reduction
in smoking. These ﬁnding were very similar to the results
of our study, although they did not report on medication
use for the treatment of stroke risk factors [11].
Previous studies have shown that guidelines for the
prevention of cardiovascular disease are less strictly
applied to women than men, mainly because the perceived
risk is lower than the calculated risk [7]. Our ﬁndings
suggest that this may also be the case in our population.
Another factor that may have prohibited stroke rates to
decline in women is that history of female hormone use
increased over time. Because previous studies have shown
that hormone replacement therapy is associated with a
higher risk of stroke in post-menopausal women [21], this
increase may have attributed to the unfavorable risk proﬁle
in women. Furthermore, although blood pressure levels
increased both in men and women, grade II hypertension
was much more frequent in women than men. This also
may have inﬂuenced stroke incidence rates in women.
Nevertheless, the decline in stroke incidence rates in men
seems somewhat paradoxical to the increase in risk factors
we observed, especially the increase in blood pressure
levels. Based on the increase in blood pressure levels alone,
one would have expected an increase in stroke incidence
rates. However, a plausible explanation is that all partici-
pants in whom hypertension was diagnosed during the
baseline visit were advised to visit their general practitioner
for blood pressure surveillance and treatment if indicated.
Therefore, blood pressure-lowering drugs will have been
described to a substantial number of participants after the
baseline examinations, resulting in lower population blood
pressure levels during follow-up. Because thresholds for
initiating blood pressure treatment decreased in the past
20 years, the beneﬁcial effect of treatment will have been
greater to the 2000 subcohort [9]. However, we also
observed favorable trends, particularly the reduction in
male cigarette smokers, which might have had a beneﬁcial
effect on stroke risk. The more widespread prescription of
preventive medication such as lipid-lowering and anti-
thrombotic medication may have contributed to the
decreased stroke incidence as well.
In conclusion, our study suggests that in Rotterdam in
the Netherlands between 1990 and 2008, stroke incidence
rates have decreased in men but not in women. The ﬁnd-
ings support the notion that preventive strategies have been
implemented quite successfully, at least in men, but also
stress the importance of recognition and treatment of stroke
risk factors in women.
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